• Quality
  • Values
  • Diversity & Inclusion
  • Cultural Competency
  • Emotional Intelligence
  • Communication
  • Excellence

Welcome to the Website of MulticultuReal® Communications

Our name speaks to our life-long indoctrination of recognizing and valuing cultural diversity, as well as the need to exhibit comfort, competence and confidence in communicating cross-culturally, and yet we do so much more. Our Philosophy anchors our message, methodologies, reputation and reality: Engaging real conversations, with real respect, building real relationships, for real results.


You are in for an interesting journey, and we are honored that you have chosen to spend a portion of your valuable time with us today.


Contact us to learn more about how MulticultuReal® Communications can partner with your organization to reach a new level of excellence.


Troy Cicero
President and Chief Skill Officer

Biotechnology from bench to business follow gen on: login | register | subscribe biobusiness ngs on way to becoming critical dx platform bioprocessing cmos focus on technology improvements drug discovery automation redefines compound management omics gene expression analysis reshapes research translational medicine animal models get closer to mimicking humans insight & intelligenceâ„¢ expert tips articles current issue past issues news new products bioperspectives multimedia webinars videos podcasts gen biolinks best of... Best of the web best science apps events polls gen news highlights more » aug 22, 2012 in search of biomarkers for diabetic kidney disease tweet keywords: biomarkers , diabetic nephropathy , kidney diseases , molecular diagnostics , proteomics international comments email this share this text this related content print this email the editor (page 1 of 1) australian firm proteomics international has won $1 million in grant funding to support its work on the discovery and development of biomarkers for diabetic kidney disease, and the development of a molecular test for diagnosing the condition and monitoring its progression in patients. The grant, from commercialization australia, will enable the firm to carry out further validation of its biomarkers in patients prior to its plan to outlicense the ip. “the currently available microalbumin test for this disease is limited in its usefulness in early diagnosis, predicting whether the patient will get the disease, and in monitoring progression,” comments richard lipscome, ph. D. , proteomics’ managing director. buy viagra online cheap cheap viagra buy generic viagra buy viagra online cheap viagra online generic viagra online buy viagra http://nationalityinworldhistory.net/bsh-buy-viagra-on-the-internet-xd/ buy cheap viagra buy cheap viagra “a companion diagnostic test that is being developed with these biomarkers may help to produce new personalized medicines, in a shorter time frame, that could deliver optimal therapy for certain groups of patients and identify those patients where medicine would be less effective or cause side effects. " proteomics international operates both as a drug discovery company and a proteomics contract service provider specializing in analytical services for the biological research market. Its in-house research is focused on the analysis of venom and venom-derived drug discovery, and the discovery and use of biomarkers from human, animal, and plant tissue. The firm’s discovery of an initial panel of 13 protein biomarkers for diabetic nephropathy was made following a three-year study of patients involved in the busselton health study. Proteomics is also leading a collaboration with the centre for food and genomic medicine to identify protein biomarkers for diabesity (diabetes and obesity).   tweet keywords: biomarkers , diabetic nephropathy , kidney diseases , molecul.
The Story